TrialRespiratory research2011

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.

Arata Azuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.